KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) Cost of Revenue (2016 - 2025)

Exact Sciences (EXAS) has disclosed Cost of Revenue for 16 consecutive years, with $262.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 4.46% to $262.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $984.2 million, a 9.58% increase, with the full-year FY2025 number at $984.2 million, up 10.08% from a year prior.
  • Cost of Revenue was $262.6 million for Q4 2025 at Exact Sciences, up from $210.3 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $274.8 million in Q4 2024 to a low of $25.6 million in Q4 2022.
  • A 5-year average of $200.6 million and a median of $211.5 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: tumbled 78.53% in 2022, then surged 747.35% in 2023.
  • Exact Sciences' Cost of Revenue stood at $119.1 million in 2021, then crashed by 78.53% to $25.6 million in 2022, then surged by 747.35% to $216.6 million in 2023, then grew by 26.88% to $274.8 million in 2024, then dropped by 4.46% to $262.6 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Cost of Revenue are $262.6 million (Q4 2025), $210.3 million (Q3 2025), and $247.1 million (Q2 2025).